How Much Does Prometrium Cost in Delaware in 2026?

Delaware Retail Pricing: What You Will Actually Pay

The sticker price for brand-name Prometrium in 2026 is approximately $180 per month, but almost no one pays that amount out of pocket in Delaware. Across the state's retail pharmacies, the average cash price for a 30-day supply of generic micronized progesterone 200 mg capsules is about $45. This pricing holds at major chains in Wilmington, Dover, and Newark, with slight variation between independent pharmacies and large retailers.

Why the gap between list price and cash price? Generic micronized progesterone capsules have been available since the early 2000s, and competition among manufacturers has driven the actual acquisition cost well below the branded figure. The FDA-approved labeling for Prometrium specifies 200 mg oral capsules for endometrial protection in postmenopausal women receiving conjugated estrogens, taken once daily at bedtime for 12 days per 28-day cycle, or 200 mg daily for secondary amenorrhea for 10 days.

Pharmacy discount programs from GoodRx, RxSaver, and SingleCare frequently bring the generic below $30 for a 30-day supply at participating Delaware locations. Costco and Walmart pharmacies tend to offer the lowest baseline pricing without a discount card, often in the $35 to $40 range. Prices shift month to month based on wholesale acquisition cost, so checking at least two pharmacies before filling is a simple way to avoid overpaying.

Insurance Coverage Across Delaware Plans

Most commercial insurance plans in Delaware cover generic micronized progesterone on a preferred tier, typically Tier 1 or Tier 2. Copays usually range from $5 to $25 depending on the plan structure. Brand-name Prometrium, when specified by a prescriber, may require a higher-tier copay or a prior authorization showing medical necessity for the branded product over generic.

Highmark Blue Cross Blue Shield of Delaware, Aetna plans sold on the Delaware Health Insurance Marketplace, and employer-sponsored plans through large carriers generally include generic progesterone without step therapy requirements. The Endocrine Society's 2022 clinical practice guideline on menopause management recommends micronized progesterone as the preferred progestogen for endometrial protection in women using estrogen therapy, which supports medical-necessity arguments when prior authorization is needed.

For women on Medicare Part D in Delaware, generic micronized progesterone typically falls on the preferred generic tier, with copays often under $10 during the initial coverage phase. The 2025 Inflation Reduction Act provisions that capped Part D out-of-pocket spending at $2,000 annually continue to apply in 2026, providing a ceiling for patients who fill multiple prescriptions.

Delaware Medicaid: Coverage with Prior Authorization

Delaware Medicaid covers Prometrium (both brand and generic micronized progesterone), but the program requires prior authorization. The PA process confirms the prescriber has documented an FDA-approved or medically accepted indication: typically endometrial protection in a patient receiving estrogen therapy, or treatment of secondary amenorrhea.

The Delaware Division of Medicaid and Medical Assistance (DMMA) processes most outpatient drug PAs within 24 hours for electronic submissions. Your prescriber submits the PA request to the pharmacy benefit manager contracted by DMMA, including the diagnosis code (ICD-10 N91.1 for secondary amenorrhea, or Z79.890 for long-term HRT). Approval is generally straightforward when the clinical indication aligns with the PEPI trial evidence (JAMA, 1995; N=875), which demonstrated that micronized progesterone 200 mg for 12 days per cycle opposed estrogen-stimulated endometrial hyperplasia as effectively as medroxyprogesterone acetate, with a more favorable lipid profile.

If the initial PA is denied, Delaware Medicaid allows a prescriber appeal. Denial rates for progesterone PAs are low when documentation includes the estrogen regimen being used, the patient's uterine status, and the specific progesterone formulation requested.

Compounded Micronized Progesterone in Delaware

Compounded micronized progesterone is available in Delaware through licensed 503A compounding pharmacies. These pharmacies operate under individual patient prescriptions, as regulated by the Delaware Board of Pharmacy and Section 503A of the Federal Food, Drug, and Cosmetic Act. A 30-day supply typically costs about $25, making compounding the lowest-cost option for many patients.

Compounded formulations offer dosing flexibility that commercial capsules do not. A compounding pharmacist can prepare progesterone in custom doses (50 mg, 75 mg, 150 mg, or other amounts), as topical creams, vaginal suppositories, or sublingual troches. This matters clinically: some women experience significant drowsiness from oral progesterone's first-pass metabolism to allopregnanolone, and a vaginal or sublingual route can reduce that sedation while still providing endometrial protection.

A few points to weigh. Compounded drugs do not undergo the same FDA approval process as commercially manufactured products. The FDA's guidance on compounding notes that compounded preparations lack the standardized bioequivalence testing required of approved generics. The American College of Obstetricians and Gynecologists (ACOG) has stated that FDA-approved formulations should be used when available and appropriate, given their documented safety and efficacy profiles.

For patients who require a non-standard dose or route, compounding fills a genuine clinical gap. For patients whose only concern is cost, the $20 difference between a generic ($45) and a compounded product ($25) should be weighed against the quality-assurance differences. Your prescriber can help determine which option is appropriate for your situation.

The AbbVie Savings Card and Other Discount Programs

AbbVie (which acquired Solvay's progesterone portfolio) offers a manufacturer savings card for brand-name Prometrium. Commercially insured patients may qualify for copay assistance that reduces out-of-pocket costs to as low as $0 to $25 per fill, depending on the program terms in effect during 2026. The card is not valid for patients on government insurance (Medicaid, Medicare, Tricare, or VA benefits).

How to use it. Patients register through the Prometrium branded website or receive a card from their prescriber's office. The pharmacist applies the card as a secondary payer at the point of sale. The discount applies per fill, and most cards have an annual maximum benefit (often $1,200 to $1,800 per year).

Beyond the manufacturer card, several other avenues exist for Delaware residents:

Pharmacy discount cards. GoodRx, RxSaver, and SingleCare each negotiate rates with Delaware retail pharmacies. These are free to use and do not require insurance. They cannot be combined with insurance copays but can sometimes beat the insured price, especially for patients with high-deductible plans who have not met their deductible.

Patient assistance programs. AbbVie's patient assistance program provides brand-name Prometrium at no cost to uninsured patients with household incomes below 200% of the federal poverty level. Application requires income documentation and a valid prescription.

340B pharmacies. Certain Federally Qualified Health Centers (FQHCs) and hospital-affiliated outpatient pharmacies in Delaware purchase drugs at the 340B discounted rate. Patients seen at these facilities may access progesterone at reduced cost regardless of insurance status. Christiana Care and several community health centers in Delaware participate in the 340B program.

Telehealth Prescribing in Delaware

Delaware permits telehealth prescribing of Prometrium and generic micronized progesterone without restrictions specific to this drug class. A licensed prescriber (physician, nurse practitioner, or physician assistant with Delaware licensure or a valid multi-state compact license) can evaluate a patient via synchronous video or audio visit and write a prescription that the patient fills at any Delaware pharmacy or through a mail-order pharmacy.

The Delaware Board of Medical Licensure and Discipline adopted permanent telehealth practice standards following the COVID-era emergency provisions, aligning with the Federation of State Medical Boards telehealth guidance. For hormone therapy prescribing, the standard of care requires a clinical evaluation that includes menstrual history, menopausal symptom assessment, contraindications screening, and a discussion of risks and benefits. This evaluation can be performed adequately via telehealth for most patients.

HealthRX and other telehealth platforms can prescribe micronized progesterone to Delaware residents after completing a clinical evaluation. The prescription is transmitted electronically to the patient's preferred pharmacy. Controlled substance rules do not apply to progesterone (it is not a scheduled drug), which simplifies the telehealth prescribing pathway compared to testosterone or other hormone therapies that carry DEA scheduling.

Clinical Background: Why Micronized Progesterone Specifically

The choice of micronized progesterone over synthetic progestins is not just a marketing preference. It reflects clinical evidence. The PEPI trial (Postmenopausal Estrogen/Progestin Interventions, JAMA 1995; N=875) was a three-year, multicenter, randomized, double-blind, placebo-controlled trial that compared conjugated equine estrogens alone, CEE plus medroxyprogesterone acetate (continuous and cyclic), and CEE plus micronized progesterone 200 mg cyclically.

The results showed that all active regimens protected against endometrial hyperplasia. Micronized progesterone, however, preserved HDL cholesterol levels better than medroxyprogesterone acetate. The CEE-plus-MPA groups saw a partial attenuation of estrogen's HDL benefit, while the CEE-plus-micronized-progesterone group maintained most of the HDL increase seen with estrogen alone.

The Women's Health Initiative (WHI) used medroxyprogesterone acetate, not micronized progesterone, in its estrogen-plus-progestin arm. The increased breast cancer risk observed in WHI has not been consistently replicated in studies using micronized progesterone. The E3N French cohort study (Fournier et al., Breast Cancer Res Treat, 2008; N=80,377) found that estrogen combined with micronized progesterone was not associated with increased breast cancer risk over a mean follow-up of 8.1 years, while estrogen combined with synthetic progestins was associated with increased risk (RR 1.69 to 95% CI 1.50 to 1.91).

The North American Menopause Society (NAMS) 2022 position statement acknowledges that micronized progesterone may carry a lower breast cancer risk than synthetic progestins, though it notes that head-to-head randomized trial data comparing breast cancer outcomes between the two progestogen types are lacking. This evidence profile is why many clinicians and patients prefer micronized progesterone for HRT, and it directly affects demand and pricing patterns.

How to Get the Best Price in Delaware: A Step-by-Step Approach

Start with your insurance formulary. Call the number on your pharmacy benefit card or log in to your plan's drug-lookup tool. Confirm whether generic micronized progesterone is on Tier 1 or Tier 2, and check if any preferred pharmacies offer a lower copay.

If you are uninsured or underinsured, compare prices across at least three pharmacies using GoodRx or RxSaver. Enter your ZIP code and the drug name ("progesterone 200 mg capsule, 30 count"). Prices in Delaware typically range from $28 to $55 depending on the pharmacy.

If cost is still a barrier, ask your prescriber about compounded micronized progesterone from a licensed 503A pharmacy. Confirm the pharmacy is registered with the Delaware Board of Pharmacy. Expect to pay around $25 per month.

For patients on Delaware Medicaid, ensure your prescriber submits the PA proactively before you arrive at the pharmacy. A rejected claim at the counter delays access by 24 to 72 hours while the PA processes.

Mail-order pharmacies often provide a 90-day supply at a lower per-unit cost than 30-day retail fills. If your insurance offers a mail-order benefit, a 90-day supply of generic progesterone may cost the equivalent of two monthly copays, yielding a 33% savings over retail.